Press Releases

News Brief

CEO of the Year | Samsung Biologics John Rim

2021 CEO of the Year | Samsung Biologics John Rim 

 

John Rim has been named “CEO of the Year” by Korea’s economic magazine, Hankyung Business, for his leadership in achieving outstanding financial performance for Samsung Biologics in 2021. 

 

Rim was credited for having delivered record-breaking revenues for two consecutive quarters in Q2 and Q3 of 2021. The market projects the company’s annual revenue and operating profit to increase 29% and 74% respectively. 

 

Rim was also credited for engaging global clients and entering into numerous CDMO contracts for various therapeutics including COVID-19 treatments and mRNA vaccines, based on the company’s excellent capabilities and technologies. 

 

Since he took over his new role in Samsung Biologics in December 2020, Rim has activitely optimized the company’s manufacturing processes to be able to respond to market demand more quickly. He continues to grow and diversify the company’s business portfolio through expansions including the building of the mRNA drug substance manufacturing suite, and the construction of the company’s fourth plant known as the ‘Super Plant’. Upon completion of the ‘Super Plant’ in 2023, Samsung Biologics will hold 620,000L of total manufacturing capacity, responsible for approximately a quarter of the entire global biopharmaceutical contract manufacturing capacity. 

 

 

John Rim has been named “CEO of the Year” by Korea’s economic magazine, Hankyung Business, for his leadership in achieving outstanding financial performance for Samsung Biologics in 2021. 

 

Rim was credited for having delivered record-breaking revenues for two consecutive quarters in Q2 and Q3 of 2021. The market projects the company’s annual revenue and operating profit to increase 29% and 74% respectively. 

 

Rim was also credited for engaging global clients and entering into numerous CDMO contracts for various therapeutics including COVID-19 treatments and mRNA vaccines, based on the company’s excellent capabilities and technologies. 

 

Since he took over his new role in Samsung Biologics in December 2020, Rim has activitely optimized the company’s manufacturing processes to be able to respond to market demand more quickly. He continues to grow and diversify the company’s business portfolio through expansions including the building of the mRNA drug substance manufacturing suite, and the construction of the company’s fourth plant known as the ‘Super Plant’. Upon completion of the ‘Super Plant’ in 2023, Samsung Biologics will hold 620,000L of total manufacturing capacity, responsible for approximately a quarter of the entire global biopharmaceutical contract manufacturing capacity. 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION